Angiotensin I

A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.

Also Known As:

Networked: 371 relevant articles (11 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Irigoyen, Maria Claudia: 3 articles (12/2012 - 01/2010)
2.	Hong, Fang: 3 articles (04/2011 - 06/2008)
3.	Campbell, Duncan J: 3 articles (02/2009 - 10/2004)
4.	Dominiczak, Anna F: 2 articles (12/2014 - 02/2004)
5.	Graham, Delyth: 2 articles (12/2014 - 02/2004)
6.	Borchers, Christoph H: 2 articles (01/2013 - 10/2010)
7.	Holmes, Daniel T: 2 articles (01/2013 - 10/2010)
8.	Machado, Ubiratan Fabres: 2 articles (12/2012 - 11/2011)
9.	Schaan, Beatriz D'Agord: 2 articles (12/2012 - 11/2011)
10.	Furuta, Takahisa: 2 articles (03/2012 - 09/2007)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/1990 - "The present study was designed to identify angiotensin I (Ang I)-forming angiotensinogenases in human extrarenal vasculature and to examine the theory of Jiménez Días on their stimulation in essential hypertension. " 01/01/2013 - "Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension." 04/01/2011 - "We aim to modulate the renin-angiotensin system (RAS) by active immunization against angiotensin I/II, potentially by a novel type of peptide--'AngI-R' for the treatment of hypertension. " 08/01/2007 - "The PRA was 8.8 ng angiotensin I (AI)/mL/h (interquartile range [IQR] 4.8-20) in malignant hypertensive patients and 2.8 ng AI/mL/h (IQR 0.6-6.3) in patients with severe hypertension (P<.01). " 03/01/2003 - "Vascular responsiveness to angiotensin I (AngI) was increased during development of hypertension in all groups of animals. "
2.	Heart Failure 10/01/2004 - "In comparison with normal subjects, heart failure subjects receiving ACE inhibitor therapy had a greater than 40-fold increase in angiotensin I levels, but angiotensin-(1-9) levels were low (1-2 fmol/ml), and similar to those of normal subjects. " 01/01/2001 - "[Angiotensin I receptor blockers for heart failure]." 09/01/1993 - "Angiotensin I and II increased peak developed force in atrial myocardial preparations obtained from patients without heart failure in a concentration-dependent manner. " 12/01/1992 - "[Treatment of congestive heart failure using angiotensin I convertase inhibitors]." 03/01/2010 - "Optimal pharmacological treatment to improve LV function was considered as: (i) angiotensin-blocking agent (ACE-I/ARB) in patients with LVEF <or=40%; (ii) ACE-I/ARB and beta-blocker in patients with LVEF <or=40% + heart failure symptoms or previous myocardial infarction; and (iii) a diuretic in patients with symptomatic heart failure, regardless of LVEF. "
3.	Hypertrophy 05/01/1994 - "Both angiotensin I and II concentrations were significantly increased with myocardial hypertrophy in the left ventricle on day 30. " 01/01/2014 - "Using a gene-trap mouse expressing a truncated version of AKAP-Lbc (due to disruption of the endogenous AKAP-Lbc gene), that abolishes PKD1 interaction with AKAP-Lbc (AKAP-Lbc-ΔPKD), we studied two mouse models of pathological hypertrophy: i) angiotensin (AT-II) and phenylephrine (PE) infusion and ii) transverse aortic constriction (TAC)-induced pressure overload. " 07/01/2007 - "To investigate the signal regulation of angiotensin I receptor on calpain system in rat hypertrophy myocardium mediated by overloaded pressure. " 08/01/2001 - "An indirect in-vivo assessment of whole body vascular hypertrophy (mean arterial pressure during maximum vasoconstriction) was made during and after drug withdrawal, as was the pressor activity evoked by angiotensin I and angiotensin II. The effect of antihypertensive treatment on microalbuminuria was also assessed during and after drug withdrawal. " 06/01/1992 - "Angiotensin I could essentially induce smooth muscle cell hypertrophy by indirect mechanisms, while angiotensins II and III act directly on smooth muscle cells."
4.	Myocardial Infarction 03/01/2010 - "Optimal pharmacological treatment to improve LV function was considered as: (i) angiotensin-blocking agent (ACE-I/ARB) in patients with LVEF <or=40%; (ii) ACE-I/ARB and beta-blocker in patients with LVEF <or=40% + heart failure symptoms or previous myocardial infarction; and (iii) a diuretic in patients with symptomatic heart failure, regardless of LVEF. " 11/01/1998 - "In addition, most importantly, we found no interaction between angiotensin II type 1 receptor A1166C gene variation and angiotensin I-converting Insertion/Deletion polymorphism, either in connection with the risk of coronary artery disease or myocardial infarction. " 01/01/1989 - "1. The effects of heart failure due to chronic myocardial infarction on the responsiveness to injected angiotensin I and ACE inhibition by intravenous cilazapril (1 mg kg-1) were evaluated. " 04/01/1994 - "To determine whether cardiac unloading by inhibition of angiotensin I (AI) to AII conversion by captopril or blockade of the AII receptor (AT1) by losartan was more effective in prevention of the detrimental hemodynamic consequences of myocardial infarction (MI), inhibition of metabolic production of AII by captopril was compared with blockade of AT1 with losartan in Sprague-Dawley rats with large MI. " 05/01/1977 - "Plasma renin activity (PRA) stimulated by upright posture was measured, in 300 men aged 45-64 years, by a radio-immunoassay of angiotensin I. The subjucts examined were divided into six groups, comparable in mean age, each containing 50 subjects: group 1, normotensives without manifest atherosclerosis; group 2, normotensives with angina pectoris definite; group 3, normotensives with a history of a transmural myocardial infarction; groups 4 to 6, patients with benign essential hypertension, without manifest atherosclerosis in group 4, with angina pectoris in group 5 and with a history of myocardial infarction in group 6. Significant differences in mean PRA were found between corresponding groups of hypertensives and normotensives, the values in hypertensives being lower. "
5.	Renal Artery Obstruction (Renal Artery Stenosis) 11/01/1990 - "Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis." 02/01/1993 - "To study regional metabolism and production of angiotensin II, we measured steady-state plasma levels of 125I-angiotensin I and II and endogenous angiotensin I and II in the aorta and the antecubital, femoral, renal, and hepatic veins during systemic infusion of 125I-angiotensin I or II. Extraction of arterially delivered angiotensin II ranged from 30-50% in the limbs to 80-100% in the renal and hepatomesenteric vascular beds both in essential hypertension (n = 13) and in unilateral renal artery stenosis (n = 7). " 05/01/1985 - "In 15 of the 16 patients found to have renal artery stenosis at angiography and cured by either revascularization or nephrectomy, Captopril stimulated both plasma renin activity and plasma angiotensin I to a far greater extent than in the majority of the 53 classified as essential hypertensives. " 11/01/1990 - "To estimate the renal extraction and de novo production of angiotensin I and to assess the contribution of blood-borne renin to renal angiotensin I production, the aortic and renal venous plasma levels of renin and intact [125I]angiotensin I and endogenous angiotensin I during continuous systemic intravenous infusion of monoiodinated [125I]angiotensin I were measured in subjects with unilateral renal artery stenosis (n = 8) who were treated with captopril (50 mg b.i.d.). " 09/22/1972 - "The elevated blood pressure induced by the renal artery stenosis can be prevented by prior treatment with the nonapeptide Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro, which blocks conversion of angiotensin I to angiotensin II. Further, the nonapeptide can restore systemic pressure to normnal in the early phase of renovascular hypertension. "

Related Drugs and Biologics

1.	Angiotensin II
2.	Renin
3.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
4.	Captopril (Capoten)
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.	Norepinephrine (Noradrenaline)
7.	Losartan (Cozaar)
8.	aliskiren
9.	Vaccines
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Nephrectomy
2.	Denervation
3.	Intravenous Infusions
4.	Surgical Instruments (Clip)
5.	Oral Administration